期刊文献+

单纯疱疹病毒2型药物敏感性测定及其阿昔洛韦耐药株的建立 被引量:2

Method for Measuring Antiviral Susceptibility of Herpes Simplex Virus Type 2 and Establishment of Resistant Strain
下载PDF
导出
摘要 目的应用空斑抑制试验测定单纯疱疹病毒2型(HSV-2)药物敏感性,并建立体外耐药病毒株。方法将HSV-2接种于乳兔肾细胞中,加入不同浓度的阿昔洛韦(ACV),培养72h后固定、染色、清点空斑数并计算药物的半数抑制浓度(IC50),通过IC50来判断HSV-2的药物敏感性。将HSV-2在含ACV环境中连续培养9代,分别在第3,6和9代测定其IC50。结果ACV对HSV-2标准株Sav毒株的IC50为1.1μg/mL。HSV-2在含ACV的环境中连续培养3代后即产生了耐药性,第3,6和9代的IC50分别为8.4μg/mL,56.9μg/mL和121.3μg/mL。结论空斑抑制试验是测定病毒药物敏感性的有效、实用的方法,建立的体外耐药病毒株可用于HSV-2的耐药性研究。 Objective To develop the method for measuring antiviral susceptibility and to establish an acyclovir(ACV) resistant herpes simplex virus type 2 (HSV-2). Methods Baby hamster kidney cells were inoculated with HSV-2, and ACV was added to the medium in various concentrations. After 72 hours incubation, plaques were counted and the 50% inhibiting concentration(IC50 )was calculated. HSV-2 was incubated in the presence of ACV for 9 passages. The IC50 of ACV was determined after the 3rd, 6th and 9th passage. Results The IC50 of ACV to HSV-2 Say was 1. 1μg/mL. In the presence of ACV, emergence of drug resistance was observed after passage 3 ; the IC50 of ACV after the 3rd, 6th and 9th passage was 8.41μg/mL,56. 9μg/mL and 121.3μg/mL respectively. Conclusion Plaque reduction assay is an efficient method for determination of antiviral drug sus- ceptibility of HSV and the establishment of ACV-resistant strain is essential for the study of resistance.
出处 《中国皮肤性病学杂志》 CAS 北大核心 2010年第3期219-220,共2页 The Chinese Journal of Dermatovenereology
基金 首都医学发展科研基金资助项目(2005-3090)
关键词 单纯疱疹病毒2型 耐药性 阿昔洛韦 空斑抑制试验 Herpes simplex virus type 2 Drug resistance Acyclovior Plaque reduction assay
  • 相关文献

参考文献8

  • 1Paz-Bailey G,Ramaswamy M,Hawkes SJ,et al.Herpes simplex virus type 2:epidemiology and management options in developing countries[J].Sex Transm Infect,2007,85(4):16-22.
  • 2Crumpacker CS,Schnipper LE,Marlowe SI,et al.Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir[J].N Engl J Med,1982,306(6):343-346.
  • 3Ziyaeyan M,Alborzi A,Japoni A,et al.Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome[J].Int J Dermatol,2007,46(12):1263-1266.
  • 4Nitta K,Shiota H,Nito T,et al.Sensitivities of other antiviral drugs and thymidine kinase activity of aciclovir-resistant herpes simplex virus type 1[J].J Jpn Ophthalmol Soc,1994,98(6):513-519.
  • 5Morfin F,Bilger K,Boucher A,et al.HSV excretion after bone marrow transplantation:a 4-year survey[J].J Clin Virol,2004,30(4):341-345.
  • 6Stranska R,Schuurman R,Nienhuis E,et al.Survey of acyclovir-resistant herpes simplex virus in the Netherlands:prevalence and characterization[J].J Clin Virol,2005,32(1):7-18.
  • 7Erard V,Wald A,Corey L,et al.Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation:impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease[J].J Infect Dis,2007,196(2):266-270.
  • 8Stanojevic M,Zerjav S,Jevtovic D,et al.Herpes simplex virus resistance to acyclovir in routine virological laboratory practice[J].Biomed Pharmacother,2005,59(3):135-136.

同被引文献17

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部